Active, not recruitingPhase 1NCT02359565
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
Studying Constitutional mismatch repair deficiency syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Eugene I HwangPediatric Brain Tumor Consortium
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 71 enrolled
- Eligibility
- 1-30 years · All sexes
- Timeline
- 2015 – 2027
Study locations (12)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
- Texas Children's Hospital, Houston, Texas, United States
- Hospital for Sick Children, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02359565 on ClinicalTrials.govOther trials for Constitutional mismatch repair deficiency syndrome
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT07523763Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGNCT07450612Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease DetectionSan Raffaele University
- RECRUITINGNANCT06215677Neoadjuvant Immunotherapy for T4 dMMR Colon CancerPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT05729646Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaYu jiren
- ACTIVE NOT RECRUITINGPHASE2NCT02983578Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerM.D. Anderson Cancer Center
See all trials for Constitutional mismatch repair deficiency syndrome →